Publication of results of the AHA-EMI in the scientific journal "The Lancet Haematology"
How can patients with acquired haemophilia A be helped as an alternative to the complication-prone standard immunosuppressive therapy?
This question was the focus of the phase 2 clinical trial AHA-EMI, scientifically led by Prof. Andreas Tiede from Hanover and coordinated by GWT as sponsor.
The study investigated whether emicizumab, a Factor VIIIa mimetic antibody, protects patients with acquired haemophilia A from bleeding and allows the postponement of immunosuppression in the first 12 weeks after diagnosis.
The results of the AHA-EMI study show that prophylaxis with emicizumab prevents bleeding in patients with acquired haemophilia A and that immunosuppressive therapy can be postponed while this treatment is given. These results are promising for a potential new treatment option for patients with acquired haemophilia A.
Congratulations to all participating centres, patients and the entire study team on this great success.